| Budget Amount *help |
¥44,850,000 (Direct Cost: ¥34,500,000、Indirect Cost: ¥10,350,000)
Fiscal Year 2019: ¥11,050,000 (Direct Cost: ¥8,500,000、Indirect Cost: ¥2,550,000)
Fiscal Year 2018: ¥11,050,000 (Direct Cost: ¥8,500,000、Indirect Cost: ¥2,550,000)
Fiscal Year 2017: ¥11,050,000 (Direct Cost: ¥8,500,000、Indirect Cost: ¥2,550,000)
Fiscal Year 2016: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have investigated the mechanism of immune checkpoint inhibition therapy and the search for new target molecules. The results showed that not only PD-L1 on tumor cells but also PD-L1 on non-tumor cells, especially PD-L1 expressed on bone marrow-derived hematopoietic cells, plays an important role in anti-tumor immunosuppression. Moreover, while the PD-L1/PD-1 pathway is a major mechanism in cancer immune escape, PD-L2 expression is elevated in tumor-associated macrophages as a compensatory mechanism when PD-L1 function is inhibited, and demonstrates immunosuppressive functions in anti-tumor responses. Furthermore, based on next-generation sequencer analysis of tumor-specific T cells, we identified several candidates of novel immune checkpoint molecule associated with T cell exhaustion.
|
